Page last updated: 2024-10-23

baclofen and Ache

baclofen has been researched along with Ache in 143 studies

Research Excerpts

ExcerptRelevanceReference
"To assess attainment of individual treatment goals one year after intrathecal baclofen (ITB) pump implantation in individuals with dyskinetic cerebral palsy (CP)."9.69Attainment of personal goals in the first year of intrathecal baclofen treatment in dyskinetic cerebral palsy: a prospective cohort study. ( Becher, JG; Bonouvrié, LA; Buizer, AI; Haberfehlner, H; Vermeulen, RJ; Vles, JSH, 2023)
"Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)."9.27Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018)
") baclofen on chronic, dysesthetic, and spasm-related pain (SRP) among patients with spinal spasticity [i."9.07Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. ( D'Luzansky, SC; Herman, RM; Ippolito, R, 1992)
"We describe a unique case of intrathecal baclofen overdose mimicking brainstem death, during bilateral anterior cingulate cortex deep brain stimulation (DBS) for pain."8.12Intrathecal baclofen overdose mimicking brainstem death during deep brain stimulation surgery for pain. ( Alamri, A; Aziz, T; Mostofi, A; Pereira, E, 2022)
"Intrathecal baclofen (ITB) pumps used to manage spasticity in children with cerebral palsy (CP) also improve pain outcomes for some but not all patients."7.96Investigating the Feasibility of a Modified Quantitative Sensory Testing Approach to Profile Sensory Function and Predict Pain Outcomes Following Intrathecal Baclofen Implant Surgery in Cerebral Palsy. ( Barney, CC; Merbler, AM; Simone, DA; Symons, FJ; Walk, D, 2020)
"To investigate the effect of intrathecal baclofen (ITB) on function and activity in dyskinetic cerebral palsy (CP)."7.88Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity. ( Askljung, B; Corneliusson, O; Eek, MN; Himmelmann, K; Lindh, K; Olsson, K; Påhlman, M, 2018)
"To compare spasticity levels, pain, sleep, fatigue, and quality of life between individuals receiving treatment with intrathecal versus oral baclofen."7.83Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life. ( Binler, D; Chu, SK; Lee, J; Marciniak, C; Mathur, SN; McCormick, ZL; Neudorf, D, 2016)
"We describe a patient in whom long-term, therapeutic infusion of the selective gamma-amino-butyric acid type B (GABAB) receptor agonist, baclofen, into the cerebrospinal fluid (CSF) gave rise to three distinct varieties of memory impairment: i) repeated, short periods of severe global amnesia, ii) accelerated long-term forgetting (ALF), evident over intervals of days and iii) a loss of established autobiographical memories."7.83The GABAB receptor agonist, baclofen, contributes to three distinct varieties of amnesia in the human brain - A detailed case report. ( Carr, M; Dewar, M; Hoefeijzers, S; Milton, F; Streatfield, C; Zeman, A, 2016)
" Our aims were to investigate the effect and mechanism of action of the GABA(B) receptor agonist, baclofen, on gastric hypersensitivity in a validated rat model of functional dyspepsia (FD)."7.77The analgesic effects of the GABAB receptor agonist, baclofen, in a rodent model of functional dyspepsia. ( Liu, LS; Pasricha, PJ; Shenoy, M, 2011)
"Baclofen, a specific GABA(B) receptor agonist, is used to treat spasticity and its off-label use includes the treatment of pain."7.75Role of GABA(B) receptor agonist baclofen in acute pain modulation during the early postnatal period. ( Franek, M; Vaculin, S, 2009)
"Seven cases of combination of intrathecal (IT) ziconotide and baclofen therapy in patients with refractory neuropathic pain and spasticity were reviewed."7.75Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports. ( Burton, AW; Danyo, DA; Frost, S; Glanzer, J; Saulino, M; Solanki, DR, 2009)
"Prospective studies that address both efficacy and safety of continuous infusion of intrathecal baclofen (CITB) in children with spastic cerebral palsy (CP), and that use outcome measures beyond muscle tone are lacking."7.75Safety and one-year efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy. ( Gorter, JW; Hoving, MA; Spincemaille, GH; van Kleef, M; van Kranen-Mastenbroek, VH; van Raak, EP; Vles, JS, 2009)
"We report on the case of a patient suffering from Friedreich's ataxia (FA) with very painful and disabling spasms that were improved markedly by intrathecal baclofen infusion."7.73Intrathecal baclofen in the treatment of painful, disabling spasms in Friedreich's ataxia. ( Ben Smail, D; Bussel, B; Denys, P; Jacq, C, 2005)
"We report the treatment of severe neuropathic pain in a patient with ED and the combined intrathecal application of baclofen and morphine in 5 patients with severe spasticity related pain."7.71Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain. ( Becker, R; Bertalanffy, H; Gatscher, S; Uhle, E, 2002)
"In this case study we describe a dual approach to the palliation of difficult muscle spasms using intrathecal baclofen via a fully implanted system, together with the homeopathic approach to symptom control."7.70Intrathecal baclofen and homeopathy for the treatment of painful muscle spasms associated with malignant spinal cord compression. ( Hicks, F; Thompson, E, 1998)
"Baclofen, an agonist of the gamma-aminobutyric acid (GABA) receptor, has antinociceptive effects, and its intrathecal administration reduces allodynic responses in animal models of neurogenic central pain."7.69A new approach to control central deafferentation pain: spinal intrathecal baclofen. ( Iseki, H; Kawabatake, H; Kawamura, H; Taira, T; Takakura, K; Tanikawa, T, 1995)
"We investigated the short-term effects of an intrathecal bolus injection of baclofen on central pain due to stroke or spinal cord injury."7.69A new approach to the control of central deafferentation pain--spinal intrathecal baclofen. ( Iseki, H; Kawabatake, H; Kawamura, H; Taira, T; Takakura, K; Tanikawa, T; Ueda, A, 1995)
"The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 microg/day (range 50 to 360 microg/day)."6.74Limitations of intrathecal baclofen for spastic hemiparesis following stroke. ( Kofler, M; Quirbach, E; Saltuari, L; Schauer, R; Singer, M, 2009)
"Clinical signs and symptoms of spasticity include hypertonia, involuntary movements (spasms, clonus), decreased range of motion, contractures, and often spasm-related pain."6.73Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. ( Bethoux, FA; Boulis, NM; Gogol, DM; Harrison, M; McClelland, S; Pioro, EP; Schwetz, KM; Stough, DK; Sutliff, MH, 2008)
"Sporadic cases of dramatic recovery from persistent vegetative state after intrathecal administration of baclofen have been reported."6.44Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. ( Hori, T; Taira, T, 2007)
"Baclofen is also used for control of dystonia due to cerebral palsy or reflex sympathetic dystrophy."6.42Clinical application of drug pump for spasticity, pain, and restorative neurosurgery: other clinical applications of intrathecal baclofen. ( Hori, T; Taira, T, 2003)
"To assess attainment of individual treatment goals one year after intrathecal baclofen (ITB) pump implantation in individuals with dyskinetic cerebral palsy (CP)."5.69Attainment of personal goals in the first year of intrathecal baclofen treatment in dyskinetic cerebral palsy: a prospective cohort study. ( Becher, JG; Bonouvrié, LA; Buizer, AI; Haberfehlner, H; Vermeulen, RJ; Vles, JSH, 2023)
"The treatment of spasticity and dystonia in these patients is difficult partly due to the relentless nature of this progressive disorder."5.48Intrathecal baclofen treatment an option in X-linked adrenoleukodystrophy. ( Ehrstedt, C; Hjartarson, HT; Tedroff, K, 2018)
"Background and Purpose- Intrathecal baclofen (ITB) is an effective treatment for managing patients with severe poststroke spasticity, who can experience continued pain and decline in their quality of life (QoL)."5.27Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity. ( Abouihia, A; Calabrese, A; Cloud, G; Creamer, M; Francisco, GE; Kossmehl, P; Saltuari, L; Ward, AB; Wissel, J; Yochelson, M; Zampolini, M, 2018)
"To determine the impact of intrathecal baclofen (ITB) therapy on outcomes of functional independence, pain, subjective improvement, performance, and standard measures of spasticity."5.11A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity. ( Guillaume, D; Roeste, G; Van Havenbergh, A; Vidal, J; Vloeberghs, M, 2005)
") baclofen on chronic, dysesthetic, and spasm-related pain (SRP) among patients with spinal spasticity [i."5.07Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study. ( D'Luzansky, SC; Herman, RM; Ippolito, R, 1992)
"This study evaluated the analgesic efficacy of baclofen in relation to specific pain stimuli in 83 women (27 nulliparas and 56 multiparas) undergoing voluntary abortion (clamping of the cervix and dilatation and curettage)."5.05Double-blind placebo-controlled trial of baclofen, alone and in combination, in patients undergoing voluntary abortion. ( Bacchini, M; Battagliarin, G; Brambilla, C; Corli, O; Di Piazza, D; Grossi, E; Roma, G, 1984)
"Ziconotide is a nonopioid intrathecal analgesic used to manage moderate to severe chronic pain."4.86Ziconotide combination intrathecal therapy: rationale and evidence. ( Deer, T; Rauck, RL; Wallace, MS, 2010)
" To date, only the antidepressants and the anticonvulsants have shown any effectiveness, albeit incomplete and inconsistent, and many questions remain unanswered: What are the exact indications for the antidepressants? What component of neuropathic pain do they relieve, and through which mechanisms? Which type of antidepressants should be prescribed? A first-generation tricyclic? Or a new compound with a selective action on serotonin reuptake? What are the effective dosage and duration of the treatment? What is it mechanism of action? What other antalgic effects do carbamazepine and baclofen possess apart from their action on trigeminal neuralgia? The opiates are generally considered to be without effect, but recent clinical and experimental findings seem to point otherwise."4.78[Pharmacological treatment of neuropathic pain]. ( Ollat, H, 1992)
"We describe a unique case of intrathecal baclofen overdose mimicking brainstem death, during bilateral anterior cingulate cortex deep brain stimulation (DBS) for pain."4.12Intrathecal baclofen overdose mimicking brainstem death during deep brain stimulation surgery for pain. ( Alamri, A; Aziz, T; Mostofi, A; Pereira, E, 2022)
"Intrathecal baclofen (ITB) pumps used to manage spasticity in children with cerebral palsy (CP) also improve pain outcomes for some but not all patients."3.96Investigating the Feasibility of a Modified Quantitative Sensory Testing Approach to Profile Sensory Function and Predict Pain Outcomes Following Intrathecal Baclofen Implant Surgery in Cerebral Palsy. ( Barney, CC; Merbler, AM; Simone, DA; Symons, FJ; Walk, D, 2020)
"To investigate the effect of intrathecal baclofen (ITB) on function and activity in dyskinetic cerebral palsy (CP)."3.88Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity. ( Askljung, B; Corneliusson, O; Eek, MN; Himmelmann, K; Lindh, K; Olsson, K; Påhlman, M, 2018)
"We describe a patient in whom long-term, therapeutic infusion of the selective gamma-amino-butyric acid type B (GABAB) receptor agonist, baclofen, into the cerebrospinal fluid (CSF) gave rise to three distinct varieties of memory impairment: i) repeated, short periods of severe global amnesia, ii) accelerated long-term forgetting (ALF), evident over intervals of days and iii) a loss of established autobiographical memories."3.83The GABAB receptor agonist, baclofen, contributes to three distinct varieties of amnesia in the human brain - A detailed case report. ( Carr, M; Dewar, M; Hoefeijzers, S; Milton, F; Streatfield, C; Zeman, A, 2016)
"To compare spasticity levels, pain, sleep, fatigue, and quality of life between individuals receiving treatment with intrathecal versus oral baclofen."3.83Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life. ( Binler, D; Chu, SK; Lee, J; Marciniak, C; Mathur, SN; McCormick, ZL; Neudorf, D, 2016)
"The following, from the 12th OESO World Conference: Cancers of the Esophagus, includes commentaries on the role for ketamine and other alternative treatments in esophageal disorders; the use of linaclotide in the treatment of esophageal pain; the alginate test as a diagnostic criterion in gastroesophageal reflux disease (GERD); the use of baclofen in treatment of GERD; the effects of opioids on the esophagus; the use of antagonists on the receptor level in GERD; the effect of local formulation of drugs on the esophageal mucosa; and the use of electroencephalographic fingerprints to predict the effect of pharmacological treatment."3.80Pharmacologic treatments for esophageal disorders. ( Blackshaw, LA; Bordin, DS; Brock, C; Brokjaer, A; Drewes, AM; Farmer, AD; Krarup, AL; Lottrup, C; Masharova, AA; Moawad, FJ; Olesen, AE, 2014)
" Systemic administration of 1 reduced acetic acid-induced writhing, the inflammatory phase of formalin-induced pain, and capsaicin-induced mechanical allodynia."3.79Antiallodynic and analgesic effects of maslinic acid, a pentacyclic triterpenoid from Olea europaea. ( Baeyens, JM; Cobos, EJ; Entrena, JM; García-Granados, A; Nieto, FR; Parra, A, 2013)
" Our aims were to investigate the effect and mechanism of action of the GABA(B) receptor agonist, baclofen, on gastric hypersensitivity in a validated rat model of functional dyspepsia (FD)."3.77The analgesic effects of the GABAB receptor agonist, baclofen, in a rodent model of functional dyspepsia. ( Liu, LS; Pasricha, PJ; Shenoy, M, 2011)
"Prospective studies that address both efficacy and safety of continuous infusion of intrathecal baclofen (CITB) in children with spastic cerebral palsy (CP), and that use outcome measures beyond muscle tone are lacking."3.75Safety and one-year efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy. ( Gorter, JW; Hoving, MA; Spincemaille, GH; van Kleef, M; van Kranen-Mastenbroek, VH; van Raak, EP; Vles, JS, 2009)
"Seven cases of combination of intrathecal (IT) ziconotide and baclofen therapy in patients with refractory neuropathic pain and spasticity were reviewed."3.75Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports. ( Burton, AW; Danyo, DA; Frost, S; Glanzer, J; Saulino, M; Solanki, DR, 2009)
"Baclofen, a specific GABA(B) receptor agonist, is used to treat spasticity and its off-label use includes the treatment of pain."3.75Role of GABA(B) receptor agonist baclofen in acute pain modulation during the early postnatal period. ( Franek, M; Vaculin, S, 2009)
"We report on the case of a patient suffering from Friedreich's ataxia (FA) with very painful and disabling spasms that were improved markedly by intrathecal baclofen infusion."3.73Intrathecal baclofen in the treatment of painful, disabling spasms in Friedreich's ataxia. ( Ben Smail, D; Bussel, B; Denys, P; Jacq, C, 2005)
"The good clinical response to treatment of spasticity and rigidity, improved quality of life, pain reduction and patient satisfaction with short length of admission demonstrate the efficacy of intrathecal baclofen therapy."3.73Continuous intrathecal baclofen administration by a fully implantable electronic pump for severe spasticity treatment: our experience. ( Bucolo, GE; Castiglione, A; Fazzio, S; Guglielmino, A; Mangiameli, S; Patti, F; Pittalà, G; Sorbello, M; Zingale, SF, 2006)
"A selective GABA(B) receptor agonist, baclofen, is known to suppress neuropathic pain."3.72Activaton of GABAB receptor inhibits the excitability of rat small diameter trigeminal root ganglion neurons. ( Ikeda, M; Kadoi, J; Matsumoto, S; Takeda, M; Tanimoto, T, 2004)
"We report the treatment of severe neuropathic pain in a patient with ED and the combined intrathecal application of baclofen and morphine in 5 patients with severe spasticity related pain."3.71Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain. ( Becker, R; Bertalanffy, H; Gatscher, S; Uhle, E, 2002)
" In vivo microdialysis was performed in parallel in awake, freely moving rats in order to evaluate possible alterations in extracellular gamma-aminobutyric acid (GABA) levels in a pain-modulating region, the medial thalamus."3.70Tiagabine antinociception in rodents depends on GABA(B) receptor activation: parallel antinociception testing and medial thalamus GABA microdialysis. ( Bartolini, A; Ipponi, A; Lamberti, C; Malmberg-Aiello, P; Medica, A, 1999)
"In this case study we describe a dual approach to the palliation of difficult muscle spasms using intrathecal baclofen via a fully implanted system, together with the homeopathic approach to symptom control."3.70Intrathecal baclofen and homeopathy for the treatment of painful muscle spasms associated with malignant spinal cord compression. ( Hicks, F; Thompson, E, 1998)
"The present study was designed to investigate the effect of a selective GABA(B) receptor agonist baclofen on the pain-like nociceptive behavior (scratching, biting and licking) induced by intrathecal (i."3.70Modulation of NMDA- and (+)TAN-67-induced nociception by GABA(B) receptors in the mouse spinal cord. ( Imai, S; Kamei, J; Nagase, H; Narita, M; Suzuki, T; Tsuda, M; Yajima, Y, 2000)
"The present data suggest that intrathecal morphine, and to some extent clonidine, but not baclofen, alleviated the abnormal pain-related behaviors in this new rat model of partial peripheral nerve injury."3.70Effects of intrathecal morphine, clonidine and baclofen on allodynia after partial sciatic nerve injury in the rat. ( Hao, JX; Wiesenfeld-Hallin, Z; Xu, IS; Xu, XJ, 1999)
"Intrathecal administration of baclofen, a GABA(B)-receptor agonist, affects pain behavior induced by formalin in a biphasic manner; baclofen at low doses enhances pain while producing antinociception at high doses."3.70Presynaptic inhibition by baclofen of miniature EPSCs and IPSCs in substantia gelatinosa neurons of the adult rat spinal dorsal horn. ( Iyadomi, I; Iyadomi, M; Kumamoto, E; Tomokuni, K; Yoshimura, M, 2000)
"Experimental studies indicate that the effects of spinal cord stimulation (SCS) on 'hypersymptoms' in neuropathic pain conditions may at least partly be mediated via GABAergic and adenosine-dependent mechanisms."3.69Modulation of spinal pain mechanisms by spinal cord stimulation and the potential role of adjuvant pharmacotherapy. ( Cui, JG; Linderoth, B; Meyerson, BA; O'Connor, WT; Segerdahl, M; Sollevi, A; Stiller, CO; Yakhnitsa, V, 1997)
"We investigated the short-term effects of an intrathecal bolus injection of baclofen on central pain due to stroke or spinal cord injury."3.69A new approach to the control of central deafferentation pain--spinal intrathecal baclofen. ( Iseki, H; Kawabatake, H; Kawamura, H; Taira, T; Takakura, K; Tanikawa, T; Ueda, A, 1995)
"In this pharmacological study we have assessed the effect of baclofen, a selective GABAB receptor agonist, on spinal expression of the immediate early gene c-Fos and the peripheral oedema evoked by a prolonged peripheral inflammation due to intraplantar carrageenan."3.69The contribution of GABAB receptor-mediated events to inflammatory pain processing: carrageenan oedema and associated spinal c-Fos expression in the rat. ( Besson, JM; Buritova, J; Chapman, V; Honoré, P, 1996)
"Baclofen, an agonist of the gamma-aminobutyric acid (GABA) receptor, has antinociceptive effects, and its intrathecal administration reduces allodynic responses in animal models of neurogenic central pain."3.69A new approach to control central deafferentation pain: spinal intrathecal baclofen. ( Iseki, H; Kawabatake, H; Kawamura, H; Taira, T; Takakura, K; Tanikawa, T, 1995)
"The present study was designed to characterise the analgesia produced by the GABA B agonist baclofen in tonic pain in monkeys."3.68GABA B mediated analgesia in tonic pain in monkeys. ( Mathur, R; Nayar, U; Sharma, R, 1993)
" The results showed that baclofen, substance P (SP) and naloxone administered intrathecally could reduce the tail pressure pain threshold."3.67Further evidence for possible analgesic mechanism of electroacupuncture: effects on neuropeptides and serotonergic neurons in rat spinal cord. ( Inoki, R; Lin, JG; Tsai, HY, 1989)
" The 5-HT released from the spinal cord was significantly increased by somatostatin, substance P and peripheral pain stimulation (tail pinch), but not affected by neurotensin, beta-endorphin and met-enkephalin."3.67Effect of neuroactive peptides on labeled 5-hydroxytryptamine release from rat spinal cord. ( Tsai, HY, 1984)
"The influence of spasticity, experienced by the patients with a spinal cord injury, on their quality of life was analyzed before the surgery and 12 months after it."3.30Neuromodulation and quality of life for patient with spasticity after spinal cord injury. ( Biktimirov, A; Bryukhovetskiy, I; Sharma, A; Sharma, HS, 2023)
"The mean daily dosage alleviating spasticity on the hemiparetic side-without affecting the nonparetic side-was 119 microg/day (range 50 to 360 microg/day)."2.74Limitations of intrathecal baclofen for spastic hemiparesis following stroke. ( Kofler, M; Quirbach, E; Saltuari, L; Schauer, R; Singer, M, 2009)
" The chronic use of this drug in a pump however proved to be technically problematic and all the adenosine cases were eventually terminated."2.73Drug-enhanced spinal stimulation for pain: a new strategy. ( Lind, G; Linderoth, B; Schechtmann, G; Winter, J, 2007)
"Clinical signs and symptoms of spasticity include hypertonia, involuntary movements (spasms, clonus), decreased range of motion, contractures, and often spasm-related pain."2.73Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief. ( Bethoux, FA; Boulis, NM; Gogol, DM; Harrison, M; McClelland, S; Pioro, EP; Schwetz, KM; Stough, DK; Sutliff, MH, 2008)
"Pain is one of the most common symptoms in children and young people (CYP) with life-limiting conditions (LLCs) which include a wide range of diagnoses including cancer."2.52Pharmacological interventions for pain in children and adolescents with life-limiting conditions. ( Beecham, E; Bluebond-Langner, M; Candy, B; Howard, R; Jones, L; Laddie, J; McCulloch, R; Rees, H; Vickerstaff, V, 2015)
"Of all drug use to treat MS symptoms, treatment for pain accounts for nearly 30 % of total use."2.49Pain and multiple sclerosis: pathophysiology and treatment. ( Messmer Uccelli, M; Solaro, C; Trabucco, E, 2013)
"These include the management of dystonia and chronic neuropathic pain."2.44Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain. ( Brennan, PM; Whittle, IR, 2008)
"Sporadic cases of dramatic recovery from persistent vegetative state after intrathecal administration of baclofen have been reported."2.44Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state. ( Hori, T; Taira, T, 2007)
"Baclofen is also used for control of dystonia due to cerebral palsy or reflex sympathetic dystrophy."2.42Clinical application of drug pump for spasticity, pain, and restorative neurosurgery: other clinical applications of intrathecal baclofen. ( Hori, T; Taira, T, 2003)
"Undertreatment of pain is a persistent clinical problem for patients with cancer."2.41[Non-opioid analgesics in cancer pain]. ( Dohi, S, 2001)
"Among the more common symptoms is spasticity."2.41Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis. ( Schapiro, RT, 2001)
"Pain is a common feature of spasticity and muscle spasms and the reasons for this are discussed in this article."2.41The management of pain in spasticity. ( Kadies, M; Ward, AB, 2002)
"They have been of value in treating pain of cancer and spasticity through spinal subarachnoid catheters."2.37Drug pumps for treatment of neurologic diseases and pain. ( Penn, RD, 1985)
"Baclofen was weaned down and switched to intrathecal ziconotide at 0."1.51Low-Dose Intrathecal Ziconotide for Spasticity From Primary Lateral Sclerosis: A Case Report. ( Goldstein, RB; Kohan, LR; Zhu, X, 2019)
"The treatment of spasticity and dystonia in these patients is difficult partly due to the relentless nature of this progressive disorder."1.48Intrathecal baclofen treatment an option in X-linked adrenoleukodystrophy. ( Ehrstedt, C; Hjartarson, HT; Tedroff, K, 2018)
"The prevalence of idiopathic vulvodynia and proctodynia is high."1.40Vulvodynia and proctodynia treated with topical baclofen 5 % and palmitoylethanolamide. ( Keppel Hesselink, JM; Kopsky, DJ; Sajben, NL, 2014)
"Pain affects quality of life, functional status, cognition, mood, sleep, and well-being."1.36Persistent non-cancer pain management in the older adult. ( Javier, N; Tomas, M, 2010)
"In trials to preserve the pharmacological profile and improve the bioavailability via lipophilicity increment of baclofen 1 and searching for more potent and less toxic muscle relaxants and analgesics, nine substituted cyclic analogues of 1 were designed and synthesized."1.355-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation. ( Abdel-Hafez, AA; Abdel-Wahab, BA, 2008)
"Treatment of spasticity with intrathecal baclofen pump implantation is a chance for clinical improvement in patients with severe spasticity."1.34[The parents expectations after baclofen pump implantation in child with severe spasticity in physical rehabilitation and psychological aspects]. ( Fafara, A; Grzegorzewski, P; Kawecka, J; Kawecki, Z; Kwiatkowski, S, 2007)
"A well known drug in the treatment of spasticity is the GABA(B) agonist Baclofen."1.31Baclofen inhibits ANP-mediated cyclic GMP synthesis in the rat cervical spinal cord. ( de Louw, AJ; de Vente, J; Steinbusch, HP; Steinbusch, HW; Troost, J; Vles, JS, 2002)
"These data also suggest that the hyperalgesia produced by high doses of baclofen does not result from disinhibition of a serotonergic pain facilitatory pathway, but rather from direct inhibition of tonically-active pain inhibitory neurons in the NRM and NGCpalpha."1.30Intrathecal methysergide antagonizes the antinociception, but not the hyperalgesia produced by microinjection of baclofen in the ventromedial medulla of the rat. ( Hammond, DL; Nelson, V; Thomas, DA, 1998)
"Diabetic animals displayed marked mechanical hyperalgesia, and some thermal hypoalgesia."1.30Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat. ( Eastwood, C; Fox, A; Gentry, C; Manning, D; Urban, L, 1999)
"]) did not change tail-flick latency in control animals but produced a dose-dependent enhancement of the antinociception induced by clonidine and morphine, and shifted their dose-response curves to the left."1.29Cromakalim differentially enhances antinociception induced by agonists of alpha(2)adrenoceptors, gamma-aminobutyric acid(B), mu and kappa opioid receptors. ( Baeyens, JM; Barrios, M; Ocaña, M, 1996)
"When baclofen was administered intraperitoneally, pretreatment with depletors of monoamines and catecholamines (reserpine, alpha-MPT) produced a marked increase in antinociceptive activity in both tests."1.27Monoamines as mediators of the antinociceptive effect of baclofen. ( Sawynok, J, 1983)
"D-Baclofen should prove to be a useful tool for investigation of the role of stereoselective baclofen receptors in a variety of pharmacological processes."1.27D-Baclofen: is it an antagonist at baclofen receptors? ( Dickson, C; Sawynok, J, 1984)
"D-Baclofen is an antagonist at spinal baclofen receptors."1.27GABAergic mechanisms in antinociception. ( Sawynok, J, 1984)
"Clonidine pretreatment did not significantly alter the effect of baclofen alone, but reversed the potentiation of the action of baclofen produced by both theophylline and isobutylmethylxanthine."1.27Clonidine reverses methylxanthine-induced potentiation of baclofen antinociception. ( Sawynok, J; Steardo, L, 1985)
"Both baclofen and clonidine were injected intraperitoneally in all experiments."1.27Role of ascending and descending noradrenergic pathways in the antinociceptive effect of baclofen and clonidine. ( Reid, A; Sawynok, J, 1986)
"The main indication was incapacitating spasticity resistant to oral treatment with baclofen and caused by spinal cord injury or lesion (11 patients), multiple sclerosis (11 patients), infantile cerebral palsy (3 patients) and cerebral injury, hypoxia or ischaemia (5 patients)."1.27Implanted pump systems for treatment of spasticity. ( Dralle, D; Müller, H; Wurdinger, T; Zierski, J, 1988)
"Acute encephalopathy and an abnormal electroencephalogram with a periodic sharp wave pattern developed in a 58-year-old woman shortly after she received a few doses of baclofen."1.27Periodic sharp waves in baclofen-induced encephalopathy. ( Benarroch, EE; Hormes, JT; Klass, DW; Rodriguez, M, 1988)

Research

Studies (143)

TimeframeStudies, this research(%)All Research%
pre-199024 (16.78)18.7374
1990's34 (23.78)18.2507
2000's47 (32.87)29.6817
2010's33 (23.08)24.3611
2020's5 (3.50)2.80

Authors

AuthorsStudies
Abdel-Hafez, AA1
Abdel-Wahab, BA1
Nieto, FR1
Cobos, EJ1
Entrena, JM1
Parra, A1
García-Granados, A1
Baeyens, JM3
Bonouvrié, LA1
Haberfehlner, H1
Becher, JG1
Vles, JSH1
Vermeulen, RJ1
Buizer, AI1
Alamri, A1
Mostofi, A1
Aziz, T1
Pereira, E1
Stone, SN1
Wei, D1
Reger, C1
Biktimirov, A1
Bryukhovetskiy, I1
Sharma, A1
Sharma, HS1
Quallo, T1
Alkhatib, O1
Gentry, C3
Andersson, DA1
Bevan, S1
Hjartarson, HT1
Ehrstedt, C1
Tedroff, K1
Eek, MN1
Olsson, K1
Lindh, K1
Askljung, B1
Påhlman, M1
Corneliusson, O1
Himmelmann, K1
Kalyvas, AV1
Drosos, E1
Korfias, S1
Gatzonis, S1
Themistocleous, M1
Sakas, DE1
Creamer, M1
Cloud, G1
Kossmehl, P1
Yochelson, M1
Francisco, GE1
Ward, AB2
Wissel, J1
Zampolini, M1
Abouihia, A1
Calabrese, A1
Saltuari, L2
Sriperumbuduri, S1
Hiremath, S1
Platt, L1
Deboer, SR1
Shenderov, K1
Probasco, JC1
Guterman, EL1
Manesh, R1
Sperati, CJ1
Berntsson, SG1
Gauffin, H1
Melberg, A1
Holtz, A1
Landtblom, AM1
Zhu, X1
Kohan, LR1
Goldstein, RB1
Barney, CC1
Merbler, AM1
Simone, DA1
Walk, D1
Symons, FJ1
Hatem, SM1
Minooee, K1
Haviv, Y1
Zadik, Y1
Sharav, Y1
Benoliel, R1
Keppel Hesselink, JM1
Kopsky, DJ1
Sajben, NL1
Scherkenbach, LA1
Coles, LD1
Patterson, EE1
Cloyd, JC1
Krach, LE1
Kriel, RL1
Blackshaw, LA1
Bordin, DS1
Brock, C1
Brokjaer, A1
Drewes, AM1
Farmer, AD1
Krarup, AL1
Lottrup, C1
Masharova, AA1
Moawad, FJ1
Olesen, AE1
Riordan, J1
Murphy, P1
Pistoia, F1
Sacco, S1
Sarà, M1
Franceschini, M1
Carolei, A1
Beecham, E1
Candy, B1
Howard, R1
McCulloch, R1
Laddie, J1
Rees, H1
Vickerstaff, V1
Bluebond-Langner, M1
Jones, L1
Martins, I1
Carvalho, P1
de Vries, MG1
Teixeira-Pinto, A1
Wilson, SP1
Westerink, BHC1
Tavares, I1
Bagmetova, VV1
Krivitskaya, AN1
Tyurenkov, IN1
Huang, D1
Huang, S2
Peers, C1
Du, X1
Zhang, H1
Gamper, N1
Bassani, AS1
Banov, D1
McCormick, ZL1
Chu, SK1
Binler, D1
Neudorf, D1
Mathur, SN1
Lee, J1
Marciniak, C1
Zeman, A1
Hoefeijzers, S1
Milton, F1
Dewar, M1
Carr, M1
Streatfield, C1
Hoving, MA1
van Raak, EP1
Spincemaille, GH1
van Kranen-Mastenbroek, VH1
van Kleef, M1
Gorter, JW1
Vles, JS2
Brennan, PM1
Whittle, IR1
Kofler, M2
Quirbach, E1
Schauer, R1
Singer, M1
Saulino, M1
Burton, AW1
Danyo, DA1
Frost, S1
Glanzer, J1
Solanki, DR1
Landry, M1
Nagy, F1
Tambeli, CH1
Levine, JD1
Gear, RW1
Franek, M1
Vaculin, S1
van der Plas, AA1
van Rijn, MA1
van Hilten, JJ1
Teasell, RW1
Mehta, S1
Aubut, JA1
Foulon, B1
Wolfe, DL1
Hsieh, JT1
Townson, AF1
Short, C1
Silva, JR1
Silva, ML1
Prado, WA1
Wallace, MS1
Rauck, RL1
Deer, T1
Tomas, M1
Javier, N1
Liu, LS1
Shenoy, M1
Pasricha, PJ1
Ucar, T1
Kazan, S1
Turgut, U1
Samanci, NK1
Kumru, H1
Flores, MC1
Portell, E1
Robles, V1
Leon, N1
Vidal, J2
Solaro, C1
Trabucco, E1
Messmer Uccelli, M1
Deseure, K1
Koek, W1
Colpaert, FC1
Adriaensen, H1
Blednov, YA1
Stoffel, M1
Alva, H1
Harris, RA1
Dickerman, RD1
Stevens, QE1
Schneider, SJ1
Turner, MS1
Taira, T6
Hori, T3
McCleane, G1
Takeda, M1
Tanimoto, T1
Ikeda, M1
Kadoi, J1
Matsumoto, S1
Dang, K1
Bowery, NG2
Urban, L3
Liu, J1
Wolfe, D1
Hao, S1
Glorioso, JC1
Mata, M1
Fink, DJ1
Ben Smail, D1
Jacq, C1
Denys, P1
Bussel, B1
Naderi, N1
Shafaghi, B1
Khodayar, MJ1
Zarindast, MR1
Akada, Y1
Mori, R1
Kato, Y1
Yamasaki, F1
Mochizuki, H1
Guillaume, D1
Van Havenbergh, A1
Vloeberghs, M1
Roeste, G1
Potes, CS1
Neto, FL1
Castro-Lopes, JM1
Guglielmino, A1
Sorbello, M1
Fazzio, S1
Zingale, SF1
Bucolo, GE1
Pittalà, G1
Castiglione, A1
Patti, F1
Mangiameli, S1
Cooper, JA1
Ridley, B1
Al Khudhairi, D1
Rababa, A1
Saddiqui, MN1
LaGraize, SC1
Fuchs, PN1
Ochiai, T1
Goto, S1
Lind, G1
Schechtmann, G1
Winter, J1
Linderoth, B3
McClelland, S1
Bethoux, FA1
Boulis, NM1
Sutliff, MH1
Stough, DK1
Schwetz, KM1
Gogol, DM1
Harrison, M1
Pioro, EP1
Sadiq, SA1
Poopatana, CA1
Müller, H2
Fafara, A1
Kwiatkowski, S1
Kawecka, J1
Grzegorzewski, P1
Kawecki, Z1
Stevenson, VL1
Sawynok, J7
Tsai, HY2
Dickson, C1
Yaksh, TL2
Reddy, SV1
McLeod, JG1
Corli, O1
Roma, G1
Bacchini, M1
Battagliarin, G1
Di Piazza, D1
Brambilla, C1
Grossi, E1
Kirubakaran, V1
Mayfield, D1
Rengachary, S1
Kirchner, P1
Menon, MK1
Clark, WG1
Vivonia, C1
Rahman, AF1
Takahashi, M1
Kaneto, H1
Ocaña, M2
Del Pozo, E1
Barrios, M2
Olausson, B1
Xu, ZQ1
Shyu, BC1
Bennett, MI1
Tai, YMA1
Symonds, JM1
Anghinah, R1
Oliveira, AS1
Gabbai, AA1
Tanikawa, T3
Kawamura, H3
Iseki, H3
Takakura, K3
Sabbe, MB1
Grafe, MR1
Pfeifer, BL1
Mirzai, TH1
Sharma, R1
Mathur, R1
Nayar, U1
Suh, HW1
Song, DK1
Son, KH1
Woo, MH1
Do, JC1
Choi, YS1
Lee, KH1
Kim, YH1
Kawabatake, H2
Ueda, A1
Buritova, J1
Chapman, V1
Honoré, P1
Besson, JM1
Cui, JG2
Meyerson, BA2
Parise, M1
García-Larrea, L1
Mertens, P1
Sindou, M1
Mauguière, F1
Nguyen, TT1
Matsumoto, K1
Watanabe, H1
Canavero, S1
Bonicalzi, V1
Hammond, DL1
Nelson, V1
Thomas, DA1
Thompson, E1
Hicks, F1
Yakhnitsa, V1
Sollevi, A1
Segerdahl, M1
Stiller, CO1
O'Connor, WT1
Zarrindast, MR3
Rezayat, M2
Ghanipoor, N1
Parvini, S2
Tabarrai, E1
Pirali, M1
Wiesenfeld-Hallin, Z2
Aldskogius, H1
Grant, G1
Hao, JX2
Hökfelt, T1
Xu, XJ2
Ipponi, A1
Lamberti, C1
Medica, A1
Bartolini, A1
Malmberg-Aiello, P1
Fox, A2
Eastwood, C1
Manning, D1
Hara, K1
Saito, Y1
Kirihara, Y1
Yamada, Y1
Sakura, S1
Kosaka, Y1
Chiang, CY1
Kwan, CL1
Hu, JW1
Sessle, BJ1
Xu, IS1
Zuniga, RE1
Schlicht, CR1
Abram, SE1
Santos, Tde J1
de Castro-Costa, CM1
Giffoni, SD1
Santos, FJ1
Ramos, RS1
Gifoni, MA1
Iyadomi, M1
Iyadomi, I1
Kumamoto, E1
Tomokuni, K1
Yoshimura, M1
Becker, R2
Uhle, EI1
Alberti, O1
Bertalanffy, H2
Yajima, Y1
Narita, M1
Tsuda, M1
Imai, S1
Kamei, J1
Nagase, H1
Suzuki, T1
Riley, RC1
Trafton, JA1
Chi, SI1
Basbaum, AI1
Schuler, V1
Lüscher, C1
Blanchet, C1
Klix, N1
Sansig, G1
Klebs, K1
Schmutz, M1
Heid, J1
Spooren, W1
Jaton, AL1
Vigouret, J1
Pozza, M1
Kelly, PH1
Mosbacher, J1
Froestl, W1
Käslin, E1
Korn, R1
Bischoff, S1
Kaupmann, K1
van der Putten, H1
Bettler, B1
Dohi, S1
Mahmoudi, M1
de Louw, AJ1
de Vente, J1
Steinbusch, HP1
Steinbusch, HW1
Troost, J1
Schapiro, RT1
Gatscher, S1
Uhle, E1
Kadies, M1
Ollat, H1
Herman, RM1
D'Luzansky, SC1
Ippolito, R1
Serrano, I1
Ruiz, RM1
Serrano, JS1
Fernández, A1
Aley, KO2
Kulkarni, SK2
Guo, ZW1
Tu, SZ1
Li, WH1
Chen, J1
Steardo, L1
Robertson, G1
Hwang, AS1
Wilcox, GL1
Lin, JG1
Inoki, R1
Penn, RD1
Abelli, L1
Conte, B1
Somma, V1
Maggi, CA1
Giuliani, S1
Meli, A1
Baraldi, M1
Zanoli, P1
Benelli, A1
Sandrini, M1
Giberti, A1
Caselgrandi, E1
Tosi, G1
Preti, C1
Reid, A1
Zierski, J1
Dralle, D1
Wurdinger, T1
Panerai, AE1
Hormes, JT1
Benarroch, EE1
Rodriguez, M1
Klass, DW1
Pelley, KA1
Vaught, JL1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment[NCT01032239]Phase 461 participants (Actual)Interventional2009-11-30Completed
Chronic Postsurgical Pain in Cerebral Palsy[NCT05764681]500 participants (Anticipated)Observational2023-03-31Not yet recruiting
Prospective, Cross Over Gabapentin vs Amitriptyline Study on Patients Suffering From Masticatory Muscle Pain[NCT02339662]Phase 450 participants (Anticipated)Interventional2015-02-28Recruiting
Dexmedetomidine Comme Adjuvant à la rachianesthésie Lors de césariennes électives : Une étude Pilote[NCT05099055]Phase 342 participants (Actual)Interventional2022-03-15Completed
Benefit of Acupuncture Combined to Regional Analgesia for Post Operative Pain Relief After Hysterectomy[NCT06002464]72 participants (Anticipated)Interventional2023-09-01Recruiting
The Use of Penile Vibratory Stimulation to Decrease Spasticity Following Spinal Cord Injury[NCT00223873]30 participants Interventional2002-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Change in Average 10 Meter Time Walking Test (10MTWT) From Baseline to Month 6

Change in average 10MTWT from baseline to month 6 beetween ITB and BMT arm. Change=10MTWT at month 6 - 10MTWT at baseline (NCT01032239)
Timeframe: Baseline and month 6

Interventionseconds (Mean)
ITB Therapy4.86
Best Medical Treatment (BMT)-2.48

Change in Average Ashworth Scale (AS) in Affected Lower Extremities From Baseline to Month 6

"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the lower extremities were assessed: hip flexors, hip adductors, knee extensors, knee flexors, plantar flexors and ankle-dorsal flexors. Average AS was calculated as the average of AS scores of the 6 muscles of the affected lower extremity. Change in average AS in affected lower extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6

Interventionunits on a scale (Mean)
ITB Therapy-0.99
Best Medical Treatment (BMT)-0.43

Change in Average Ashworth Scale (AS) in Affected Upper Extremities From Baseline to Month 6

"AS is a manual test, measuring the resistance to passive movement about a joint with varying degrees of velocity. Scores range from 1-5, with 5 choices. A score of 1 indicates no resistance, and 5 indicates rigidity. The following muscle groups in the upper extremities were assessed: wrist flexors, elbow flexors, elbow extensors, shoulder abductors and shoulder adductors. Average AS was calculated as the average of AS scores of the 5 muscles of the affected lower extremities. Change in average AS in affected upper extremities from baseline to month 6 between ITB and BMT arm was assessed.~Change= AS at month 6 - AS at baseline." (NCT01032239)
Timeframe: Baseline and month 6

Interventionunits on a scale (Mean)
ITB Therapy-0.66
Best Medical Treatment (BMT)-0.17

Change in Functional Independence Measure (FIM) Score From Baseline to Month 6

FIM contains 18 items composed of 13 motor tasks and 5 cognitive tasks. Tasks are rated on a 7-point ordinal scale that ranges from total assistance (or complete dependence) to complete independence. Ratings should reflect actual observed performance, not capability. Total score ranges from 18 (lowest) to 126 (highest) level of independence. Change in FIM total score from baseline to month 6 between ITB and BMT arm was assessed. Change=FIM score at month 6 - FIM score at baseline. (NCT01032239)
Timeframe: Baseline and month 6

Interventionunits on a scale (Mean)
ITB Therapy2.68
Best Medical Treatment (BMT)-2.58

Change in Stroke Specific Quality of Life (SS-QoL ) From Baseline to Month 6

"SS-QoL questionnaire is a self-assessed quality of life questionnaire specifically designed for post-stroke patients. It evaluates 49 items across 12-domains: personality, energy, language, mobility, vision, upper extremity function, thinking, mood, work/productivity, self-care, and family and social roles. Each item is rated on a 5-point Likert Scale, measuring either positive or negative response to a statement. Summary score is composed of an unweighted average of the 12 domain scores, with higher scores indicating better QoL. Total score ranges from 1 to 5. Change in SS-QoL summary score from baseline to month 6 between ITB and BMT arm was assessed.~Change=SS-QoL score at month 6 - SS-QoL score at baseline." (NCT01032239)
Timeframe: Baseline and month 6

Interventionunits on a scale (Mean)
ITB Therapy0.26
Best Medical Treatment (BMT)0.05

Change in Euro QoL Group-5 Dimensional, 3 Level Version (EQ-5D-3L) From Baseline to Month 6

"The EQ-5D-3L is a generic measure of health status consisting in the EQ-5D-3L descriptive system and the EQ visual analogue scale (EQ VAS). The EQ-5D-3L descriptive system is characterized on five dimensions: mobility, self-care, ability to undertake usual activities, pain and anxiety/depression. Patients were asked to indicate their level of health on each dimension using one of three levels: no health problems, moderate health problems, and severe health problems. Responses from the questionnaire were converted to a single health index utility score; this ranges from -0.595 to 1. EQ VAS records the patient's self-rated health on a vertical visual analogue scale from 0 to 100 where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0). Change in EQ-5D-3L utility score and VAS score from baseline to month 6 between ITB and BMT arm were assessed. Change=EQ-5D-3L utility or VAS score at month 6 - EQ-5D-3L utility or VAS score." (NCT01032239)
Timeframe: Baseline and month 6

,
Interventionunits on a scale (Mean)
Utility ScoreVAS
Best Medical Treatment (BMT)0.014.40
ITB Therapy0.099.68

Change in Numeric Pain Rating Scale (NPRS) From Baseline to Month 6

"NPRS is designed to assess the level of pain a patient is feeling at a point in time. The following questions has been presented to patients: What is your actual spasticity-related or spasm-related pain? What was your least spasticity-related or spasm-related pain during the last week? What was your worst spasticity-related or spasm-related pain during the last week? The patient indicated how much pain he is feeling on a scale from 0 to 10. A score of 0 (zero) is no pain while a score of 10 (ten) is worst possible pain. Change in NPRS related to actual, least or worst pain from baseline to month 6 between ITB and BMT arm was assessed. Change=NPRS at month 6 - NPRS at baseline." (NCT01032239)
Timeframe: Baseline and month 6

,
Interventionunits on a scale (Mean)
Actual painLeast PainWorst Pain
Best Medical Treatment (BMT)0.000.24-0.04
ITB Therapy-1.17-1.61-1.35

Change in SF-12 (12-item Short Form) From Baseline to Month 6

The SF-12 is generic assessment of health-related quality of life, which evaluates 8 health dimensions (physical functioning, role physical, bodily pain, vitality, social functioning, role emotional, mental health, and general health). Subscale scores for each dimension were aggregated into summary scores for physical (PCS) and mental health (MCS) components (ranging from 0 to 100, with higher scores indicating better health). Changes in the PCS and MCS from baseline to Month 6 were both compared between the BMT and ITB arms. Change=SF-12 score at month 6 - SF-12 score at baseline. (NCT01032239)
Timeframe: Baseline and month 6

,
Interventionunits on a scale (Mean)
PCSMCS
Best Medical Treatment (BMT)-1.13-0.82
ITB Therapy3.131.05

Healthcare Resource Utilization

Number of patients with healthcare professional contacts outside of study visits in the ITB and BMT between baseline and months 6 (NCT01032239)
Timeframe: baseline, ITB test (only ITB arm), second assessment (only BMT arm), week 6 (only ITB arm), month 3, month 6

,
InterventionParticipants (Count of Participants)
Baseline : general practitionerBaseline : neurologistBaseline : nurse (hospital setting)Baseline : nurse (home care)Baseline : orthopedic surgeonBaseline : otherITB test:general practitionerITB test: neurologistITB test :otherSecond Assessment: general practitionerSecond Assessment: neurologistSecond Assessment: nurse (home care)Second Assessment: otherweek 6: general practitionerweek 6: nurse (hospital setting)week 6: othermonth 3: general practitionermonth 3: neurologistmonth 3: othermonth 6: general practitionermonth 6: neurologistmonth 6: other
Best Medical Treatment (BMT)8801013NANANA5114NANANA8397211
ITB Therapy14410310113NANANANA422716838

Number of Participants Who Were Able to Transfer From the Wheelchair to Bed Without Human Assistance

Patient was asked to transfer from the wheelchair to bed without human assistance. High level functional patient (HLP) could transfer. Low level functional patient (LLP) was not able to transfer. Comparison of the number and percentage of HLP and LLP between ITB and BMT arms was evaluated. (NCT01032239)
Timeframe: baseline, month 3, month 6

InterventionParticipants (Count of Participants)
Baseline72364475Baseline72364476Month 372364475Month 372364476Month 672364475Month 672364476
HLPLLP
ITB Therapy22
Best Medical Treatment (BMT)24
ITB Therapy9
Best Medical Treatment (BMT)21
ITB Therapy6
ITB Therapy19
Best Medical Treatment (BMT)19
ITB Therapy5
Best Medical Treatment (BMT)5

Therapy Satisfaction

"Patients were presented with two statements (I am satisfied with the reduction in spasticity provided by my treatment, and I would recommend this therapy to a friend). They agreed, disagreed or were neutral with the statements." (NCT01032239)
Timeframe: month 6

InterventionParticipants (Count of Participants)
Patient Satisfaction with Spasticity Reduction72364475Patient Satisfaction with Spasticity Reduction72364476Patient Therapy Reccomandation72364475Patient Therapy Reccomandation72364476
disagreeneutralagree
ITB Therapy2
Best Medical Treatment (BMT)7
ITB Therapy4
ITB Therapy16
Best Medical Treatment (BMT)11
Best Medical Treatment (BMT)5
ITB Therapy3
Best Medical Treatment (BMT)4
Best Medical Treatment (BMT)14

Reviews

21 reviews available for baclofen and Ache

ArticleYear
The case for cautious consumption: NSAIDs in chronic kidney disease.
    Current opinion in nephrology and hypertension, 2019, Volume: 28, Issue:2

    Topics: Acute Kidney Injury; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Baclofen; Cost-Ben

2019
Intrathecal baclofen: effects on spasticity, pain, and consciousness in disorders of consciousness and locked-in syndrome.
    Current pain and headache reports, 2015, Volume: 19, Issue:1

    Topics: Baclofen; Consciousness; Consciousness Disorders; Drug Administration Schedule; Humans; Injections,

2015
Pharmacological interventions for pain in children and adolescents with life-limiting conditions.
    The Cochrane database of systematic reviews, 2015, Mar-13, Issue:3

    Topics: Adolescent; Alendronate; Baclofen; Botulinum Toxins, Type A; Cerebral Palsy; Child; Child, Preschool

2015
Intrathecal baclofen therapy for neurological disorders: a sound knowledge base but many challenges remain.
    British journal of neurosurgery, 2008, Volume: 22, Issue:4

    Topics: Adult; Baclofen; Catheterization; Cerebral Palsy; Child; Child, Preschool; Dose-Response Relationshi

2008
[GABA(B) receptors and sensitization to pain].
    Journal de la Societe de biologie, 2009, Volume: 203, Issue:1

    Topics: 14-3-3 Proteins; Allosteric Regulation; Animals; Baclofen; Calcium Channels; Calcium-Binding Protein

2009
A systematic review of pharmacologic treatments of pain after spinal cord injury.
    Archives of physical medicine and rehabilitation, 2010, Volume: 91, Issue:5

    Topics: Analgesics; Anticonvulsants; Antidepressive Agents; Baclofen; Cannabinoids; Humans; Pain; Spinal Cor

2010
Ziconotide combination intrathecal therapy: rationale and evidence.
    The Clinical journal of pain, 2010, Volume: 26, Issue:7

    Topics: Analgesics; Baclofen; Clonidine; Drug Therapy, Combination; Humans; Injections, Spinal; Morphine; om

2010
Pain and multiple sclerosis: pathophysiology and treatment.
    Current neurology and neuroscience reports, 2013, Volume: 13, Issue:1

    Topics: Analgesics, Opioid; Anticonvulsants; Antidepressive Agents; Baclofen; Cannabinoids; Fatigue; Humans;

2013
Intrathecal drug delivery 2002.
    Acta neurochirurgica. Supplement, 2003, Volume: 87

    Topics: Baclofen; Drug Approval; Humans; Infusion Pumps, Implantable; Injections, Spinal; Morphine; Movement

2003
Clinical application of drug pump for spasticity, pain, and restorative neurosurgery: other clinical applications of intrathecal baclofen.
    Acta neurochirurgica. Supplement, 2003, Volume: 87

    Topics: Baclofen; Cerebrovascular Circulation; Dystonia; Electric Stimulation Therapy; Humans; Infusion Pump

2003
Pharmacological management of neuropathic pain.
    CNS drugs, 2003, Volume: 17, Issue:14

    Topics: Analgesics, Opioid; Anesthetics, Local; Anticonvulsants; Antidepressive Agents, Tricyclic; Baclofen;

2003
GABAB receptor: a site of therapeutic benefit.
    Current opinion in pharmacology, 2006, Volume: 6, Issue:1

    Topics: Animals; Baclofen; Brain; Clinical Trials as Topic; Cognition; Drug Evaluation, Preclinical; Epileps

2006
Intrathecal baclofen in the treatment of post-stroke central pain, dystonia, and persistent vegetative state.
    Acta neurochirurgica. Supplement, 2007, Volume: 97, Issue:Pt 1

    Topics: Baclofen; Dystonia; Humans; Muscle Relaxants, Central; Pain; Persistent Vegetative State; Stroke

2007
Functional effects of spinal baclofen.
    Przeglad lekarski, 2007, Volume: 64 Suppl 2

    Topics: Adolescent; Adult; Aged; Aged, 80 and over; Baclofen; Child; Child, Preschool; Female; GABA Agonists

2007
Relief of symptoms in end-stage neurological conditions.
    British journal of hospital medicine (London, England : 2005), 2007, Volume: 68, Issue:12

    Topics: Baclofen; Clinical Trials, Phase I as Topic; Cognition Disorders; Deglutition Disorders; Humans; Moo

2007
The neurochemistry of central pain: evidence from clinical studies, hypothesis and therapeutic implications.
    Pain, 1998, Volume: 74, Issue:2-3

    Topics: Anesthetics, Intravenous; Baclofen; Cerebral Cortex; GABA Agonists; gamma-Aminobutyric Acid; Glutami

1998
[Non-opioid analgesics in cancer pain].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59, Issue:9

    Topics: Adrenergic alpha-Agonists; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antide

2001
Management of spasticity, pain, and paroxysmal phenomena in multiple sclerosis.
    Current neurology and neuroscience reports, 2001, Volume: 1, Issue:3

    Topics: Acetates; Amines; Autoimmune Diseases; Baclofen; Benzodiazepines; Botulinum Toxins, Type A; Cannabin

2001
The management of pain in spasticity.
    Disability and rehabilitation, 2002, May-20, Volume: 24, Issue:8

    Topics: Administration, Oral; Analgesics; Baclofen; Botulinum Toxins; Humans; Injections, Spinal; Muscle Rel

2002
[Pharmacological treatment of neuropathic pain].
    Revue neurologique, 1992, Volume: 148, Issue:8-9

    Topics: Anesthetics, Local; Anticonvulsants; Antidepressive Agents; Baclofen; Capsaicin; Chronic Disease; Di

1992
Drug pumps for treatment of neurologic diseases and pain.
    Neurologic clinics, 1985, Volume: 3, Issue:2

    Topics: Alzheimer Disease; Baclofen; Bethanechol; Bethanechol Compounds; Catheters, Indwelling; Chronic Dise

1985

Trials

13 trials available for baclofen and Ache

ArticleYear
Attainment of personal goals in the first year of intrathecal baclofen treatment in dyskinetic cerebral palsy: a prospective cohort study.
    Disability and rehabilitation, 2023, Volume: 45, Issue:8

    Topics: Baclofen; Cerebral Palsy; Child; Cohort Studies; Dystonia; Goals; Humans; Injections, Spinal; Muscle

2023
Ultrasound guidance versus landmark guidance for intrathecal baclofen pump refill: A randomized pilot study.
    PM & R : the journal of injury, function, and rehabilitation, 2023, Volume: 15, Issue:11

    Topics: Adolescent; Baclofen; Humans; Pain; Pilot Projects; Ultrasonography; Ultrasonography, Interventional

2023
Neuromodulation and quality of life for patient with spasticity after spinal cord injury.
    International review of neurobiology, 2023, Volume: 172

    Topics: Baclofen; Female; Humans; Male; Muscle Relaxants, Central; Muscle Spasticity; Pain; Quality of Life;

2023
Effect of Intrathecal Baclofen on Pain and Quality of Life in Poststroke Spasticity.
    Stroke, 2018, Volume: 49, Issue:9

    Topics: Administration, Oral; Aged; Baclofen; Benzodiazepines; Clonidine; Dantrolene; Female; Humans; Infusi

2018
Limitations of intrathecal baclofen for spastic hemiparesis following stroke.
    Neurorehabilitation and neural repair, 2009, Volume: 23, Issue:1

    Topics: Adolescent; Adult; Baclofen; Child; Dose-Response Relationship, Drug; Female; GABA Agonists; Gait Di

2009
A clinical study of intrathecal baclofen using a programmable pump for intractable spasticity.
    Archives of physical medicine and rehabilitation, 2005, Volume: 86, Issue:11

    Topics: Adolescent; Adult; Aged; Baclofen; Child; Child, Preschool; Cognition; Female; Humans; Infusion Pump

2005
Drug-enhanced spinal stimulation for pain: a new strategy.
    Acta neurochirurgica. Supplement, 2007, Volume: 97, Issue:Pt 1

    Topics: Animals; Baclofen; Dose-Response Relationship, Drug; Electric Stimulation; Follow-Up Studies; GABA A

2007
Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief.
    Muscle & nerve, 2008, Volume: 37, Issue:3

    Topics: Adult; Aged; Amyotrophic Lateral Sclerosis; Baclofen; Cohort Studies; Female; Humans; Infusion Pumps

2008
Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity.
    Journal of neurology, 2007, Volume: 254, Issue:10

    Topics: Adult; Baclofen; Drug Therapy, Combination; Female; Humans; Injections, Spinal; Male; Middle Aged; M

2007
Double-blind placebo-controlled trial of baclofen, alone and in combination, in patients undergoing voluntary abortion.
    Clinical therapeutics, 1984, Volume: 6, Issue:6

    Topics: Abortion, Induced; Adolescent; Adult; Baclofen; Clinical Trials as Topic; Diazepam; Dilatation and C

1984
Spinal intrathecal baclofen suppresses central pain after a stroke.
    Journal of neurology, neurosurgery, and psychiatry, 1994, Volume: 57, Issue:3

    Topics: Baclofen; Cerebrovascular Disorders; Female; Humans; Injections, Spinal; Male; Middle Aged; Pain; Pa

1994
Intrathecal baclofen is analgesic in patients with chronic pain.
    Anesthesiology, 2000, Volume: 92, Issue:3

    Topics: Aged; Amputation, Surgical; Baclofen; Cerebral Palsy; Chronic Disease; Female; GABA Agonists; Hemato

2000
Intrathecal baclofen suppresses central pain in patients with spinal lesions. A pilot study.
    The Clinical journal of pain, 1992, Volume: 8, Issue:4

    Topics: Adult; Baclofen; Double-Blind Method; Female; Humans; Injections, Spinal; Male; Middle Aged; Pain; R

1992

Other Studies

109 other studies available for baclofen and Ache

ArticleYear
5-(4-Chlorophenyl)-5,6-dihydro-1,3-oxazepin-7(4H)-one derivatives as lipophilic cyclic analogues of baclofen: design, synthesis, and neuropharmacological evaluation.
    Bioorganic & medicinal chemistry, 2008, Sep-01, Volume: 16, Issue:17

    Topics: Animals; Baclofen; Cognition Disorders; Cyclization; Dose-Response Relationship, Drug; Drug Design;

2008
Antiallodynic and analgesic effects of maslinic acid, a pentacyclic triterpenoid from Olea europaea.
    Journal of natural products, 2013, Apr-26, Volume: 76, Issue:4

    Topics: Analgesics; Animals; Capsaicin; gamma-Aminobutyric Acid; Hyperalgesia; Inflammation; Mice; Molecular

2013
Intrathecal baclofen overdose mimicking brainstem death during deep brain stimulation surgery for pain.
    Annals of the Royal College of Surgeons of England, 2022, Volume: 104, Issue:8

    Topics: Adult; Baclofen; Bradycardia; Brain Stem; Deep Brain Stimulation; Humans; Infusion Pumps, Implantabl

2022
G protein βγ subunits inhibit TRPM3 ion channels in sensory neurons.
    eLife, 2017, 08-15, Volume: 6

    Topics: Analgesics, Opioid; Animals; Baclofen; Calcium; Capsaicin; CHO Cells; Cricetulus; Electrophysiology;

2017
Intrathecal baclofen treatment an option in X-linked adrenoleukodystrophy.
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2018, Volume: 22, Issue:1

    Topics: Adrenoleukodystrophy; Baclofen; Child; Dystonia; Dystonic Disorders; Humans; Infusion Pumps, Implant

2018
Intrathecal baclofen in dyskinetic cerebral palsy: effects on function and activity.
    Developmental medicine and child neurology, 2018, Volume: 60, Issue:1

    Topics: Baclofen; Cerebral Palsy; Child; Dystonia; Female; Humans; Injections, Spinal; Male; Motor Activity;

2018
Intrathecal Baclofen Therapy for Painful Muscle Spasms in a Patient with Friedreich's Ataxia.
    Stereotactic and functional neurosurgery, 2018, Volume: 96, Issue:2

    Topics: Aged; Baclofen; Female; Follow-Up Studies; Friedreich Ataxia; Humans; Injections, Spinal; Muscle Rel

2018
Egad!
    Journal of hospital medicine, 2019, Volume: 14, Issue:3

    Topics: Aged; Baclofen; Colchicine; Diagnosis, Differential; Female; Gout; Hallux; Hospitalization; Humans;

2019
Inherited Ataxia and Intrathecal Baclofen for the Treatment of Spasticity and Painful Spasms.
    Stereotactic and functional neurosurgery, 2019, Volume: 97, Issue:1

    Topics: Adult; Aged; Baclofen; Female; Friedreich Ataxia; Humans; Injections, Spinal; Male; Middle Aged; Mus

2019
Low-Dose Intrathecal Ziconotide for Spasticity From Primary Lateral Sclerosis: A Case Report.
    A&A practice, 2019, Jul-01, Volume: 13, Issue:1

    Topics: Adult; Baclofen; Female; Humans; Injections, Spinal; Motor Neuron Disease; Muscle Spasticity; omega-

2019
Investigating the Feasibility of a Modified Quantitative Sensory Testing Approach to Profile Sensory Function and Predict Pain Outcomes Following Intrathecal Baclofen Implant Surgery in Cerebral Palsy.
    Pain medicine (Malden, Mass.), 2020, 01-01, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Baclofen; Cerebral Palsy; Child; Feasibility Studies; Female; Humans; Infusion Pu

2020
Has the time come for using intrathecal baclofen in neuropathic pain?
    European journal of pain (London, England), 2013, Volume: 17, Issue:7

    Topics: Baclofen; Evoked Potentials; Female; Humans; Male; Pain; Pain Perception; Spinal Cord Injuries

2013
Painful traumatic trigeminal neuropathy: an open study on the pharmacotherapeutic response to stepped treatment.
    Journal of oral & facial pain and headache, 2014,Winter, Volume: 28, Issue:1

    Topics: Amines; Amitriptyline; Analgesics; Analgesics, Non-Narcotic; Baclofen; Carbamazepine; Clinical Proto

2014
Vulvodynia and proctodynia treated with topical baclofen 5 % and palmitoylethanolamide.
    Archives of gynecology and obstetrics, 2014, Volume: 290, Issue:2

    Topics: Administration, Topical; Adult; Amides; Anti-Inflammatory Agents, Non-Steroidal; Anus Diseases; Bacl

2014
Pharmacokinetics and pharmacodynamics of intravenous baclofen in dogs: a preliminary study.
    The Journal of pharmacy and pharmacology, 2014, Volume: 66, Issue:7

    Topics: Animals; Area Under Curve; Baclofen; Biological Availability; Dogs; Dose-Response Relationship, Drug

2014
Pharmacologic treatments for esophageal disorders.
    Annals of the New York Academy of Sciences, 2014, Volume: 1325

    Topics: Analgesics, Opioid; Animals; Baclofen; Enteric Nervous System; Esophageal Diseases; Gastroesophageal

2014
Intrathecal Pump: An Abrupt Intermittent Pump Failure.
    Neuromodulation : journal of the International Neuromodulation Society, 2015, Volume: 18, Issue:5

    Topics: Adult; Baclofen; Equipment Failure; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; M

2015
GABA acting on GABAB receptors located in a medullary pain facilitatory area enhances nociceptive behaviors evoked by intraplantar formalin injection.
    Pain, 2015, Volume: 156, Issue:8

    Topics: Animals; Baclofen; Disease Models, Animal; Formaldehyde; GABA-B Receptor Agonists; GABA-B Receptor A

2015
Effects of Phenibut and Citrocard on Non-Competitive and Competitive Behavior during Provoked Aggression in Animals.
    Bulletin of experimental biology and medicine, 2015, Volume: 159, Issue:1

    Topics: Agonistic Behavior; Animal Communication; Animals; Avoidance Learning; Baclofen; Competitive Behavio

2015
GABAB receptors inhibit low-voltage activated and high-voltage activated Ca(2+) channels in sensory neurons via distinct mechanisms.
    Biochemical and biophysical research communications, 2015, Sep-18, Volume: 465, Issue:2

    Topics: Animals; Baclofen; Calcium Channels, L-Type; Calcium Channels, N-Type; Calcium Channels, T-Type; Dit

2015
Evaluation of the Percutaneous Absorption of Ketamine HCl, Gabapentin, Clonidine HCl, and Baclofen, in Compounded Transdermal Pain Formulations, Using the Franz Finite Dose Model.
    Pain medicine (Malden, Mass.), 2016, Volume: 17, Issue:2

    Topics: Administration, Cutaneous; Aged; Amines; Baclofen; Clonidine; Cyclohexanecarboxylic Acids; Drug Comp

2016
Intrathecal Versus Oral Baclofen: A Matched Cohort Study of Spasticity, Pain, Sleep, Fatigue, and Quality of Life.
    PM & R : the journal of injury, function, and rehabilitation, 2016, Volume: 8, Issue:6

    Topics: Baclofen; Cohort Studies; Cross-Sectional Studies; Female; Humans; Injections, Spinal; Male; Middle

2016
The GABAB receptor agonist, baclofen, contributes to three distinct varieties of amnesia in the human brain - A detailed case report.
    Cortex; a journal devoted to the study of the nervous system and behavior, 2016, Volume: 74

    Topics: Amnesia; Analgesics; Baclofen; Female; Humans; Memory, Episodic; Memory, Short-Term; Middle Aged; Pa

2016
Safety and one-year efficacy of intrathecal baclofen therapy in children with intractable spastic cerebral palsy.
    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society, 2009, Volume: 13, Issue:3

    Topics: Adolescent; Baclofen; Cerebral Palsy; Child; Female; Follow-Up Studies; Humans; Infusion Pumps, Impl

2009
Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports.
    European journal of physical and rehabilitation medicine, 2009, Volume: 45, Issue:1

    Topics: Adult; Baclofen; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Muscle Relaxants, Cen

2009
Centralization of noxious stimulus-induced analgesia (NSIA) is related to activity at inhibitory synapses in the spinal cord.
    Pain, 2009, Volume: 143, Issue:3

    Topics: Analgesics; Animals; Baclofen; Capsaicin; Drug Interactions; GABA Agonists; GABA Antagonists; GABA-B

2009
Role of GABA(B) receptor agonist baclofen in acute pain modulation during the early postnatal period.
    Pharmacology, 2009, Volume: 84, Issue:2

    Topics: Acute Disease; Age Factors; Animals; Baclofen; Disease Models, Animal; Dose-Response Relationship, D

2009
Baclofen-induced chorea in complex regional pain syndrome-related dystonia.
    Movement disorders : official journal of the Movement Disorder Society, 2010, May-15, Volume: 25, Issue:7

    Topics: Baclofen; Chorea; Dystonia; Female; Humans; Male; Middle Aged; Muscle Relaxants, Central; Pain

2010
Analgesia induced by 2- or 100-Hz electroacupuncture in the rat tail-flick test depends on the activation of different descending pain inhibitory mechanisms.
    The journal of pain, 2011, Volume: 12, Issue:1

    Topics: Adjuvants, Anesthesia; Adrenergic alpha-Antagonists; Analgesia; Anesthetics, Intravenous; Animals; A

2011
Persistent non-cancer pain management in the older adult.
    Medicine and health, Rhode Island, 2010, Volume: 93, Issue:7

    Topics: Aged, 80 and over; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Baclofen; Drug Thera

2010
The analgesic effects of the GABAB receptor agonist, baclofen, in a rodent model of functional dyspepsia.
    Neurogastroenterology and motility, 2011, Volume: 23, Issue:4

    Topics: Analgesics; Animals; Baclofen; Disease Models, Animal; Dyspepsia; Electromyography; GABA-A Receptor

2011
Outcomes of intrathecal baclofen (ITB) therapy in spacticity.
    Turkish neurosurgery, 2011, Volume: 21, Issue:1

    Topics: Adolescent; Adult; Baclofen; Child; Child, Preschool; Disability Evaluation; Female; Follow-Up Studi

2011
Effect of intrathecal baclofen on evoked pain perception: an evoked potentials and quantitative thermal testing study.
    European journal of pain (London, England), 2013, Volume: 17, Issue:7

    Topics: Adolescent; Adult; Baclofen; Evoked Potentials; Female; Humans; Injections, Spinal; Male; Middle Age

2013
The 5-HT(1A) receptor agonist F 13640 attenuates mechanical allodynia in a rat model of trigeminal neuropathic pain.
    European journal of pharmacology, 2002, Dec-05, Volume: 456, Issue:1-3

    Topics: Aminopyridines; Animals; Baclofen; Behavior, Animal; Disease Models, Animal; Dose-Response Relations

2002
A pervasive mechanism for analgesia: activation of GIRK2 channels.
    Proceedings of the National Academy of Sciences of the United States of America, 2003, Jan-07, Volume: 100, Issue:1

    Topics: Analgesia; Analgesics; Animals; Baclofen; Benzoxazines; Clonidine; Crosses, Genetic; Ethanol; Female

2003
The role of surgical placement and pump orientation in intrathecal pump system failure: a technical report.
    Pediatric neurosurgery, 2003, Volume: 38, Issue:2

    Topics: Analgesia, Epidural; Baclofen; Catheters, Indwelling; Cerebral Palsy; Child; Device Removal; Equipme

2003
Activaton of GABAB receptor inhibits the excitability of rat small diameter trigeminal root ganglion neurons.
    Neuroscience, 2004, Volume: 123, Issue:2

    Topics: Animals; Baclofen; Cells, Cultured; GABA Agonists; GABA Antagonists; Membrane Potentials; Neurons; P

2004
Interaction of gamma-aminobutyric acid receptor type B receptors and calcium channels in nociceptive transmission studied in the mouse hemisected spinal cord in vitro: withdrawal symptoms related to baclofen treatment.
    Neuroscience letters, 2004, May-06, Volume: 361, Issue:1-3

    Topics: Action Potentials; Afferent Pathways; Animals; Baclofen; Calcium Channel Blockers; Calcium Channels;

2004
Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain.
    Molecular therapy : the journal of the American Society of Gene Therapy, 2004, Volume: 10, Issue:1

    Topics: Animals; Baclofen; Bicuculline; Calcitonin Gene-Related Peptide; gamma-Aminobutyric Acid; Ganglia, S

2004
Intrathecal baclofen in the treatment of painful, disabling spasms in Friedreich's ataxia.
    Movement disorders : official journal of the Movement Disorder Society, 2005, Volume: 20, Issue:6

    Topics: Adult; Baclofen; Electromyography; Friedreich Ataxia; Humans; Male; Muscle Relaxants, Central; Pain;

2005
Interaction between gamma-aminobutyric acid GABAB and cannabinoid CB1 receptors in spinal pain pathways in rat.
    European journal of pharmacology, 2005, May-09, Volume: 514, Issue:2-3

    Topics: Analysis of Variance; Animals; Baclofen; Cyclohexanols; Dose-Response Relationship, Drug; Drug Inter

2005
Analgesic properties of the novel compound M43068 in rat models of acute and neuropathic pain.
    European journal of pharmacology, 2005, Oct-31, Volume: 523, Issue:1-3

    Topics: Adrenergic alpha-Antagonists; Analgesics; Animals; Baclofen; Behavior, Animal; Disease Models, Anima

2005
Inhibition of pain behavior by GABA(B) receptors in the thalamic ventrobasal complex: effect on normal rats subjected to the formalin test of nociception.
    Brain research, 2006, Oct-18, Volume: 1115, Issue:1

    Topics: Acute Disease; Analgesics; Animals; Baclofen; Behavior, Animal; Chronic Disease; Disease Models, Ani

2006
Continuous intrathecal baclofen administration by a fully implantable electronic pump for severe spasticity treatment: our experience.
    Minerva anestesiologica, 2006, Volume: 72, Issue:10

    Topics: Adult; Aged; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle

2006
Response of intrathecal baclofen resistance to dose reduction.
    Neurology, 2006, Oct-24, Volume: 67, Issue:8

    Topics: Adult; Analgesics; Anticonvulsants; Baclofen; Dose-Response Relationship, Drug; Drug Resistance; Dru

2006
Intrathecal baclofen for muscle spasticity and pain--two case reports.
    Middle East journal of anaesthesiology, 2006, Volume: 18, Issue:5

    Topics: Adult; Baclofen; Female; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male; Middle Aged;

2006
GABAA but not GABAB receptors in the rostral anterior cingulate cortex selectively modulate pain-induced escape/avoidance behavior.
    Experimental neurology, 2007, Volume: 204, Issue:1

    Topics: Animals; Avoidance Learning; Baclofen; Bicuculline; Escape Reaction; GABA Agonists; GABA Antagonists

2007
Fifteen year experience of intrathecal baclofen treatment in Japan.
    Acta neurochirurgica. Supplement, 2006, Volume: 99

    Topics: Baclofen; Brain Injuries; Child; Humans; Injections, Spinal; Japan; Male; Muscle Relaxants, Central;

2006
[The parents expectations after baclofen pump implantation in child with severe spasticity in physical rehabilitation and psychological aspects].
    Przeglad lekarski, 2007, Volume: 64 Suppl 2

    Topics: Activities of Daily Living; Adult; Baclofen; Cerebral Palsy; Child; Female; Follow-Up Studies; Hemip

2007
GABAergic mechanisms in antinociception.
    Progress in neuro-psychopharmacology & biological psychiatry, 1984, Volume: 8, Issue:4-6

    Topics: Alkynes; Aminocaproates; Aminooxyacetic Acid; Analgesics; Animals; Baclofen; Bicuculline; Central Ne

1984
Effect of neuroactive peptides on labeled 5-hydroxytryptamine release from rat spinal cord.
    Proceedings of the National Science Council, Republic of China. Part B, Life sciences, 1984, Volume: 8, Issue:2

    Topics: Animals; Baclofen; beta-Endorphin; Endorphins; Enkephalin, Methionine; Male; Naloxone; Neuropeptides

1984
D-Baclofen: is it an antagonist at baclofen receptors?
    Progress in neuro-psychopharmacology & biological psychiatry, 1984, Volume: 8, Issue:4-6

    Topics: Analgesics; Animals; Baclofen; Injections, Intraperitoneal; Injections, Spinal; Male; Pain; Rats; Ra

1984
Studies in the primate on the analgetic effects associated with intrathecal actions of opiates, alpha-adrenergic agonists and baclofen.
    Anesthesiology, 1981, Volume: 54, Issue:6

    Topics: Adrenergic alpha-Agonists; Analgesia; Animals; Avoidance Learning; Baclofen; Behavior, Animal; Cats;

1981
When drugs can help in multiple sclerosis.
    Drugs, 1980, Volume: 19, Issue:6

    Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Baclofen; Dantrolene; Diazepam; Humans; Immuno

1980
Dyskinesia and psychosis in a patient following baclofen withdrawal.
    The American journal of psychiatry, 1984, Volume: 141, Issue:5

    Topics: Adult; Baclofen; Humans; Male; Movement Disorders; Muscle Spasticity; Pain; Paraplegia; Psychoses, S

1984
Monoamines as mediators of the antinociceptive effect of baclofen.
    Naunyn-Schmiedeberg's archives of pharmacology, 1983, Volume: 323, Issue:1

    Topics: alpha-Methyltyrosine; Analgesics; Animals; Baclofen; Biogenic Amines; Male; Methyltyrosines; Pain; R

1983
[Tasks and problems of general medical care in certain groups of disorders. Patients with mixed (motor and sensory) paralyses--from a neurological viewpoint].
    Zeitschrift fur arztliche Fortbildung, 1982, Jun-01, Volume: 76, Issue:11

    Topics: Baclofen; Demyelinating Diseases; Diazepam; Electrogalvanism, Intraoral; Exercise Therapy; Hemiplegi

1982
Interaction between phencyclidine (PCP) and GABA-ergic drugs: clinical implications.
    Pharmacology, biochemistry, and behavior, 1980, Volume: 12, Issue:1

    Topics: Aminooxyacetic Acid; Anesthesia; Animals; Baclofen; Dextroamphetamine; Diazepam; Drug Interactions;

1980
Role of GABAergic systems in the development of morphine tolerance in formalin-treated mice.
    Japanese journal of pharmacology, 1995, Volume: 68, Issue:2

    Topics: Analgesics, Opioid; Animals; Baclofen; Bicuculline; Diazepam; Drug Tolerance; Flumazenil; Formaldehy

1995
Subgroups among mu-opioid receptor agonists distinguished by ATP-sensitive K+ channel-acting drugs.
    British journal of pharmacology, 1995, Volume: 114, Issue:6

    Topics: 4-Aminopyridine; Adenosine Triphosphate; Animals; Baclofen; Benzopyrans; Cromakalim; Female; Mice; N

1995
Dorsal column inhibition of nociceptive thalamic cells mediated by gamma-aminobutyric acid mechanisms in the cat.
    Acta physiologica Scandinavica, 1994, Volume: 152, Issue:3

    Topics: Afferent Pathways; Animals; Baclofen; Cats; Dental Pulp; Electric Stimulation; GABA-A Receptor Antag

1994
Staphylococcal meningitis following Synchromed intrathecal pump implant: a case report.
    Pain, 1994, Volume: 56, Issue:2

    Topics: Adolescent; Baclofen; Cerebral Palsy; Humans; Infusion Pumps, Implantable; Injections, Spinal; Male;

1994
Effect of baclofen on pain in diabetic neuropathy.
    Muscle & nerve, 1994, Volume: 17, Issue:8

    Topics: Adult; Baclofen; Diabetic Neuropathies; Humans; Male; Middle Aged; Pain

1994
Toxicology of baclofen continuously infused into the spinal intrathecal space of the dog.
    Neurotoxicology, 1993,Winter, Volume: 14, Issue:4

    Topics: Animal Nutritional Physiological Phenomena; Animals; Baclofen; Cardiovascular System; Defecation; Do

1993
GABA B mediated analgesia in tonic pain in monkeys.
    Indian journal of physiology and pharmacology, 1993, Volume: 37, Issue:3

    Topics: Analgesics; Animals; Baclofen; Dose-Response Relationship, Drug; Formaldehyde; Macaca mulatta; Male;

1993
Antinociceptive effect of smilaxin B administered intracerebroventricularly in the mouse.
    Planta medica, 1996, Volume: 62, Issue:2

    Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Animals; Baclofen; Cerebral Ventricles; Dizocilpine Maleate; G

1996
A new approach to the control of central deafferentation pain--spinal intrathecal baclofen.
    Acta neurochirurgica. Supplement, 1995, Volume: 64

    Topics: Afferent Pathways; Aged; Baclofen; Cerebrovascular Disorders; Dose-Response Relationship, Drug; Drug

1995
The contribution of GABAB receptor-mediated events to inflammatory pain processing: carrageenan oedema and associated spinal c-Fos expression in the rat.
    Neuroscience, 1996, Volume: 73, Issue:2

    Topics: Animals; Baclofen; Carrageenan; Dose-Response Relationship, Drug; Edema; GABA Agonists; Gene Express

1996
Cromakalim differentially enhances antinociception induced by agonists of alpha(2)adrenoceptors, gamma-aminobutyric acid(B), mu and kappa opioid receptors.
    The Journal of pharmacology and experimental therapeutics, 1996, Volume: 276, Issue:3

    Topics: Animals; Baclofen; Benzopyrans; Cromakalim; Dose-Response Relationship, Drug; Female; Mice; Mice, In

1996
Effects of spinal cord stimulation on touch-evoked allodynia involve GABAergic mechanisms. An experimental study in the mononeuropathic rat.
    Pain, 1996, Volume: 66, Issue:2-3

    Topics: Animals; Baclofen; Electric Stimulation; GABA Agonists; GABA Antagonists; GABA-A Receptor Agonists;

1996
A new approach to control central deafferentation pain: spinal intrathecal baclofen.
    Stereotactic and functional neurosurgery, 1995, Volume: 65, Issue:1-4

    Topics: Afferent Pathways; Aged; Baclofen; Central Nervous System; Cerebrovascular Disorders; Female; GABA A

1995
Clinical use of polysynaptic flexion reflexes in the management of spasticity with intrathecal baclofen.
    Electroencephalography and clinical neurophysiology, 1997, Volume: 105, Issue:2

    Topics: Adult; Baclofen; Dose-Response Relationship, Drug; Female; Humans; Infusion Pumps; Injections, Spina

1997
Involvement of supraspinal GABA-ergic systems in clonidine-induced antinociception in the tail-pinch test in mice.
    Life sciences, 1997, Volume: 61, Issue:11

    Topics: Adrenergic alpha-2 Receptor Agonists; Analgesics; Animals; Baclofen; Bicuculline; Clonidine; GABA An

1997
Intrathecal methysergide antagonizes the antinociception, but not the hyperalgesia produced by microinjection of baclofen in the ventromedial medulla of the rat.
    Neuroscience letters, 1998, Mar-13, Volume: 244, Issue:2

    Topics: Analgesics; Animals; Baclofen; GABA-B Receptor Antagonists; Hyperalgesia; Injections, Spinal; Male;

1998
Intrathecal baclofen and homeopathy for the treatment of painful muscle spasms associated with malignant spinal cord compression.
    Palliative medicine, 1998, Volume: 12, Issue:2

    Topics: Aged; Baclofen; Holistic Health; Homeopathy; Humans; Injections, Spinal; Male; Muscle Relaxants, Cen

1998
Modulation of spinal pain mechanisms by spinal cord stimulation and the potential role of adjuvant pharmacotherapy.
    Stereotactic and functional neurosurgery, 1997, Volume: 68, Issue:1-4 Pt 1

    Topics: Adenosine; Animals; Baclofen; Behavior, Animal; Chemotherapy, Adjuvant; Combined Modality Therapy; D

1997
Interactions between antinociception induced by cholecystokinin antagonists and GABA agonists in the tail-flick test.
    Pharmacology & toxicology, 1998, Volume: 83, Issue:4

    Topics: Animals; Baclofen; Benzodiazepinones; Devazepide; Dose-Response Relationship, Drug; Drug Interaction

1998
Effects of CCK antagonists on GABA mechanism-induced antinociception in the formalin test.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1999, Volume: 9, Issue:1-2

    Topics: Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Baclofen; Dose-Response Relationship, Drug; F

1999
Central inhibitory dysfunctions: mechanisms and clinical implications.
    The Behavioral and brain sciences, 1997, Volume: 20, Issue:3

    Topics: Animals; Baclofen; Central Nervous System; Cholecystokinin; GABA Agonists; Hormone Antagonists; Indo

1997
Tiagabine antinociception in rodents depends on GABA(B) receptor activation: parallel antinociception testing and medial thalamus GABA microdialysis.
    European journal of pharmacology, 1999, Mar-05, Volume: 368, Issue:2-3

    Topics: Abdomen; Animals; Baclofen; Constriction, Pathologic; Dose-Response Relationship, Drug; Escape React

1999
Critical evaluation of the streptozotocin model of painful diabetic neuropathy in the rat.
    Pain, 1999, Volume: 81, Issue:3

    Topics: Animals; Baclofen; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; H

1999
The interaction of antinociceptive effects of morphine and GABA receptor agonists within the rat spinal cord.
    Anesthesia and analgesia, 1999, Volume: 89, Issue:2

    Topics: Analgesics, Opioid; Animals; Baclofen; Colon; Dose-Response Relationship, Drug; Drug Interactions; D

1999
Effects of GABA receptor antagonist on trigeminal caudalis nociceptive neurons in normal and neonatally capsaicin-treated rats.
    Journal of neurophysiology, 1999, Volume: 82, Issue:5

    Topics: Animals; Animals, Newborn; Baclofen; Bicuculline; Brain Mapping; Capsaicin; Functional Laterality; G

1999
Effects of intrathecal morphine, clonidine and baclofen on allodynia after partial sciatic nerve injury in the rat.
    Acta anaesthesiologica Scandinavica, 1999, Volume: 43, Issue:10

    Topics: Analgesics; Analgesics, Opioid; Animals; Baclofen; Clonidine; Cold Temperature; Dose-Response Relati

1999
The effect of baclofen on spontaneous and evoked behavioural expression of experimental neuropathic chronic pain.
    Arquivos de neuro-psiquiatria, 1999, Volume: 57, Issue:3B

    Topics: Animals; Baclofen; Behavior, Animal; Chronic Disease; GABA Agonists; Male; Naloxone; Narcotic Antago

1999
Presynaptic inhibition by baclofen of miniature EPSCs and IPSCs in substantia gelatinosa neurons of the adult rat spinal dorsal horn.
    Pain, 2000, Volume: 85, Issue:3

    Topics: Animals; Baclofen; Dose-Response Relationship, Drug; Electrophysiology; Evoked Potentials; Excitator

2000
Continuous intrathecal baclofen infusion in the management of central deafferentation pain.
    Journal of pain and symptom management, 2000, Volume: 20, Issue:5

    Topics: Baclofen; Female; GABA Agonists; Humans; Injections, Spinal; Middle Aged; Multiple Sclerosis, Chroni

2000
Modulation of NMDA- and (+)TAN-67-induced nociception by GABA(B) receptors in the mouse spinal cord.
    Life sciences, 2000, Dec-29, Volume: 68, Issue:6

    Topics: Analgesics; Animals; Baclofen; Dizocilpine Maleate; Dose-Response Relationship, Drug; Excitatory Ami

2000
Presynaptic regulation of spinal cord tachykinin signaling via GABA(B) but not GABA(A) receptor activation.
    Neuroscience, 2001, Volume: 103, Issue:3

    Topics: Animals; Baclofen; Dose-Response Relationship, Drug; GABA-B Receptor Agonists; Male; Neurons; Nocice

2001
Epilepsy, hyperalgesia, impaired memory, and loss of pre- and postsynaptic GABA(B) responses in mice lacking GABA(B(1)).
    Neuron, 2001, Jul-19, Volume: 31, Issue:1

    Topics: Animals; Animals, Newborn; Avoidance Learning; Baclofen; Body Temperature Regulation; Delta Rhythm;

2001
GABA mechanisms and antinociception in mice with ligated sciatic nerve.
    Pharmacology & toxicology, 2001, Volume: 89, Issue:2

    Topics: Animals; Baclofen; Bicuculline; Dose-Response Relationship, Drug; Drug Interactions; GABA Agonists;

2001
Baclofen inhibits ANP-mediated cyclic GMP synthesis in the rat cervical spinal cord.
    Neuroscience letters, 2002, Mar-15, Volume: 321, Issue:1-2

    Topics: Aging; Animals; Atrial Natriuretic Factor; Baclofen; Cervical Vertebrae; Cyclic GMP; GABA Agonists;

2002
Combined intrathecal baclofen and morphine infusion for the treatment of spasticity related pain and central deafferentiation pain.
    Acta neurochirurgica. Supplement, 2002, Volume: 79

    Topics: Afferent Pathways; Analgesics, Opioid; Baclofen; Central Nervous System Diseases; Denervation; Drug

2002
GABAergic and cholinergic mediation in the antinociceptive action of homotaurine.
    General pharmacology, 1992, Volume: 23, Issue:3

    Topics: Acetates; Acetic Acid; Analgesics; Animals; Baclofen; gamma-Aminobutyric Acid; Immersion; Male; Mice

1992
Baclofen analgesia in mice: a GABAB-mediated response.
    Methods and findings in experimental and clinical pharmacology, 1991, Volume: 13, Issue:10

    Topics: Analgesia; Animals; Baclofen; Female; GABA-A Receptor Antagonists; Male; Mice; Naloxone; Organophosp

1991
[Studies of synthesis and structure-activity relationships of analogs of the muscle relaxant--baclofen].
    Yao xue xue bao = Acta pharmaceutica Sinica, 1990, Volume: 25, Issue:1

    Topics: Animals; Baclofen; Female; Male; Mice; Muscle Relaxation; Pain; Receptors, GABA-A; Sensory Threshold

1990
Clonidine reverses methylxanthine-induced potentiation of baclofen antinociception.
    Pharmacology, biochemistry, and behavior, 1985, Volume: 22, Issue:5

    Topics: 1-Methyl-3-isobutylxanthine; Animals; Baclofen; Clonidine; Drug Interactions; Male; Neural Pathways;

1985
Desensitization to substance P following intrathecal injection. A technique for investigating the role of substance P in nociception.
    Naunyn-Schmiedeberg's archives of pharmacology, 1985, Volume: 331, Issue:2-3

    Topics: Animals; Baclofen; Injections, Spinal; Male; Morphine; Pain; Rats; Rats, Inbred Strains; Sensory Thr

1985
Intradermal hypertonic saline-induced behavior as a nociceptive test in mice.
    Life sciences, 1986, Jun-30, Volume: 38, Issue:26

    Topics: Animals; Anti-Inflammatory Agents; Baclofen; Behavior, Animal; Dose-Response Relationship, Drug; Inj

1986
Further evidence for possible analgesic mechanism of electroacupuncture: effects on neuropeptides and serotonergic neurons in rat spinal cord.
    Japanese journal of pharmacology, 1989, Volume: 49, Issue:2

    Topics: Acupuncture Therapy; Analgesia, Epidural; Animals; Baclofen; Electric Stimulation; Enkephalin, Methi

1989
GABAergic agents-induced antinociceptive effect in mice.
    Methods and findings in experimental and clinical pharmacology, 1989, Volume: 11, Issue:10

    Topics: Analgesics; Animals; Baclofen; Bicuculline; Female; gamma-Aminobutyric Acid; Male; Mice; Morphine; M

1989
A method for studying pain arising from the urinary bladder in conscious, freely-moving rats.
    The Journal of urology, 1989, Volume: 141, Issue:1

    Topics: Animals; Baclofen; Behavior, Animal; Consciousness; Female; Morphine; Nociceptors; Pain; Rats; Sensa

1989
Baclofen activates two distinct receptors in the rat spinal cord and guinea pig ileum.
    Neuropharmacology, 1986, Volume: 25, Issue:7

    Topics: Amino Acids; Amino Acids, Neutral; Animals; Baclofen; Ileum; Male; Pain; Rats; Rats, Inbred Strains;

1986
Neurobehavioral, neuroendocrine and neurochemical effects of zinc supplementation in rats.
    Advances in experimental medicine and biology, 1986, Volume: 203

    Topics: Adrenocorticotropic Hormone; Animals; Baclofen; Behavior, Animal; beta-Endorphin; Brain; Diazepam; E

1986
Role of ascending and descending noradrenergic pathways in the antinociceptive effect of baclofen and clonidine.
    Brain research, 1986, Oct-29, Volume: 386, Issue:1-2

    Topics: Afferent Pathways; Animals; Baclofen; Central Nervous System; Clonidine; Efferent Pathways; Hydroxyd

1986
Implanted pump systems for treatment of spasticity.
    Acta neurochirurgica. Supplementum, 1988, Volume: 43

    Topics: Adolescent; Adult; Aged; Baclofen; Child; Child, Preschool; Drug Administration Schedule; Equipment

1988
[Potentiation concept in pharmacology].
    Minerva anestesiologica, 1988, Volume: 54, Issue:4

    Topics: 5-Hydroxytryptophan; Animals; Baclofen; Clomipramine; Diazepam; Drug Synergism; Drug Therapy, Combin

1988
Periodic sharp waves in baclofen-induced encephalopathy.
    Archives of neurology, 1988, Volume: 45, Issue:7

    Topics: Baclofen; Brain Diseases; Electroencephalography; Female; Humans; Middle Aged; Muscular Diseases; Pa

1988
An antinociceptive profile of kojic amine: an analogue of gamma-aminobutyric acid (GABA).
    Neuropharmacology, 1987, Volume: 26, Issue:4

    Topics: Animals; Atropine; Atropine Derivatives; Baclofen; gamma-Aminobutyric Acid; Isoxazoles; Male; Mice;

1987